Minimally invasive surgery (MIS) is being validated for pancreatic cancer, impacting how surgeons approach patient selection and procedures.

• 22 out of 28 statements on MIS received over 90% expert agreement, enhancing surgical guidance.
• The consensus includes recommendations for left pancreatectomy, pancreatoduodenectomy, and total pancreatectomy tailored for cancer.

Surgeons can adopt these evidence-based practices to improve patient outcomes and program implementation.

• Insights on evaluating patients and integrating innovation in surgical techniques are also provided.